The new research, published in CVIR Oncology, pooled nine years of experience from three specialist centers in the United Kingdom, the United States, and Spain. The retrospective analysis drew on a prospectively maintained database of patients treated with percutaneous IRE between May 2015 and October 2024, using the NanoKnife 3.0 System. Every case involved a biopsy-proven renal cell carcinoma that a multidisciplinary tumor board had deemed unsuitable for partial or radical nephrectomy, or for conventional thermal ablation, typically because the tumor pressed against vital structures, sat within a solitary kidney, or the patient carried significant comorbidities.

The cohort comprised 68 patients with a mean age of 66.9 years, harboring 71 tumors with a mean diameter of 2.83 centimeters. These were not simple lesions: the median RENAL Nephrometry score, a standardized measure of anatomical complexity, was 9, placing them among the most challenging tumors treated anywhere. Nearly 58 percent were entirely endophytic, meaning they grew wholly within the kidney’s interior, and almost half were hilar tumors touching the renal artery or vein. Strikingly, 93 percent of the tumors lay less than one millimeter from a vital structure, including the ureter, colon, renal vessels, collecting system, and in rare cases the inferior vena cava, liver, small bowel, or spleen.

IRE works in a fundamentally different way from the radiofrequency, cryoablation, and microwave techniques that dominate image-guided ablation. Rather than heating or freezing tissue, the technology delivers high-voltage electrical impulses through fine needles placed around the tumor under ultrasound or CT guidance. These pulses create irreversible nanopores in the lipid membranes of cancer cells, disrupting cellular homeostasis, causing loss of intracellular contents and ultimately triggering apoptotic cell death. Crucially, the technique spares structures rich in collagen, such as ureters, blood vessels, and bile ducts, because their architecture does not depend on the cellular membranes that the pulses destroy. It also avoids the heat-sink effect, in which flowing blood dissipates thermal energy and undermines ablation near large vessels.

The procedure itself is technically demanding. Patients undergo general anesthesia with deep neuromuscular blockade to ensure complete muscle paralysis, since the electrical pulses would otherwise provoke violent contractions. Interventional radiologists, each with more than a decade of ablation experience, inserted an average of 4.56 monopolar electrodes to bracket each tumor. A test run of 20 pulses per electrode pair confirmed electrical conductivity, allowing adjustment of voltage to keep delivered current between 20 and 40 amperes, before the full treatment of 90 pulses per electrode pair was delivered with cardiac gating. Mean anesthesia time was 107 minutes, and patients typically stayed 1.6 days in hospital.

The headline results were encouraging. Technical success, meaning complete coverage of the tumor by the ablation zone, was achieved in 100 percent of sessions. Primary technique efficacy, defined as no residual enhancing tumor at the one-month scan, was 77.5 percent. While that figure trails some earlier single-center series, the authors emphasize that their tumors were larger and far more complex than those in comparable studies, and efficacy fell significantly as tumor size rose, particularly beyond 3.5 centimeters. Importantly, the modest primary efficacy did not translate into poor long-term cancer control: when residual disease was salvaged with a single additional ablation session, local control reached 95.8 percent, and five-year local tumor progression-free survival stood at 84.4 percent, rising to 81.1 percent at seven years.

Safety data were equally notable. Only two major adverse events occurred among 71 procedures, a rate of 2.8 percent: one permanent ureteric injury requiring long-term stenting and one episode of hematuria that resolved after stent removal. By comparison, published series of cryoablation for completely endophytic tumors report major complication rates approaching 10 percent, and robotic partial nephrectomy series report grade 3 or higher complications of around 17.5 percent. Kidney function was well preserved, with a mean decline in estimated glomerular filtration rate of just 7.5 ml/min/1.73m2, and only 10 percent of patients experiencing a clinically significant drop of more than 25 percent. Oncological durability was also reassuring, with cancer-specific survival of 98 percent at five years and metastasis-free survival of 91 percent.

Perhaps the most striking finding came from the composite ‘trifecta’ outcome, borrowed from surgical practice and combining primary efficacy, absence of major complications, and less than 25 percent decline in kidney function. IRE achieved the trifecta in 68.6 percent of cases, exceeding the 58.8 percent reported for thermal ablation and the 65.3 percent for robotic partial nephrectomy in comparable multicenter analyses of endophytic tumors. The authors suggest this may reflect IRE’s inherent suitability for tumors hugging critical structures, though they caution that head-to-head prospective comparisons are still needed before declaring superiority. They also describe practical refinements, including placing the electrode nearest a vital structure as the anode so pulses fire away from it, and using pre-operative ureteric stents in high-risk cases to guard against injury.

The study is not without limitations. It was retrospective, lacked a contemporaneous control group, involved only four operators across three centers, and did not employ centralized imaging review. Its results apply most directly to the kind of complex, high-risk tumors referred to specialist centers. Nevertheless, as the largest and longest-followed series of IRE for renal cancer to date, it provides the strongest real-world evidence yet that this electric-pulse technology deserves a firm place in the kidney cancer toolkit. For the growing population of patients with tumors once considered untreatable without sacrificing a kidney, the message from this nine-year, three-country experience is clear: irreversible electroporation can destroy the cancer while preserving both the organ and its function.

Subject of Research: Real-world outcomes of irreversible electroporation for complex small renal cell carcinomas unsuitable for surgery or thermal ablation

Article Title: MulticentRe rEal World outcomes of IrReversible Electroporation for complex small kiDney cancers (REWIRED)

Article References: MulticentRe rEal World outcomes of IrReversible Electroporation for complex small kiDney cancers (REWIRED). (n.d.). https://doi.org/10.1007/s44343-026-00049-z

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00049-z

Keywords: irreversible electroporation, kidney cancer, renal cell carcinoma, image-guided ablation, small renal mass, NanoKnife, interventional radiology, nephron-sparing treatment, cryoablation, partial nephrectomy, RENAL nephrometry score, trifecta outcome

One of the most conceptually striking studies targets the tumor microenvironment itself. Researchers developed and evaluated a PET imaging approach aimed at CD163, a surface marker carried by tumor-associated macrophages, the immune cells that tumors frequently recruit and reprogram to support their own growth. In head and neck squamous cell carcinoma, a malignancy in which the immune landscape often determines how patients respond to therapy, a tracer labeled with copper-64, known as 64Cu-ICT-01, allowed investigators to visualize where these macrophages reside and how their distribution shifts during tumor progression and after treatment. Complementary testing on human tissue confirmed that the tracer binds specifically to CD163, supporting its translational relevance. If validated further, the technique could give oncologists a noninvasive window into immunosuppressive niches within tumors, potentially helping predict which patients will benefit from immunotherapy long before changes in tumor size become apparent.

Theranostics, the pairing of diagnostic imaging with targeted radionuclide therapy, features prominently in the new research. A prospective clinical trial evaluated 177Lu-LNC1010, a long-acting somatostatin analog labeled with lutetium-177, for peptide receptor radionuclide therapy in 22 patients with progressive metastatic neuroendocrine tumors. Long-acting formulations are designed to prolong tumor exposure to the therapeutic radiation while simplifying treatment logistics, and in this trial patients received up to four cycles. The investigators systematically assessed safety, tumor response, absorbed radiation doses delivered to tumors and organs at risk, progression-free survival and overall survival during follow-up. The results add to rapidly growing evidence that radioligand therapy can deliver clinically meaningful disease control in neuroendocrine tumors, a class of cancers that has historically been difficult to treat with conventional chemotherapy.

A second radiopharmaceutical study turned its attention to CEACAM5, a cell-surface protein overexpressed in several cancers, including colorectal cancer, and an established target for both antibody-drug conjugates and radioligand therapy. In laboratory and mouse experiments, a radiolabeled compound designed to bind CEACAM5 selectively attached to CEACAM5-positive cancer cells while demonstrating favorable tumor uptake and reduced accumulation in the kidneys, a critical safety consideration for peptide- and antibody-based radionuclide therapies. Remarkably, a single treatment significantly extended survival in mice bearing CEACAM5-positive tumors, with only mild and temporary toxicity observed. The findings position this agent as a candidate for translation into first-in-human trials and reinforce the broader trend of matching radiopharmaceuticals to molecular signatures rather than tumor locations.

Pediatric oncology also gained a potential new target. Neuroblastoma, an aggressive cancer of the sympathetic nervous system that primarily affects young children, remains one of the most challenging malignancies to image and treat. Researchers examined DLL3, a protein better known from small cell lung cancer, as a candidate target in neuroblastoma. Analysis of human tumor samples and preclinical models revealed that DLL3 is widely expressed and frequently localized on the cell surface, an essential prerequisite for both imaging agents and therapeutic radioligands. DLL3-targeted PET imaging subsequently demonstrated tumor-specific uptake not only in preclinical models but also in four patients with relapsed neuroblastoma, offering early clinical proof of concept. For children with few remaining options, a validated DLL3 pathway could open the door to both molecular imaging and precision radioligand therapy in the future.

Beyond theranostics, several new studies interrogate the reliability of the workhorse technology of molecular imaging itself. Amyloid PET, used to detect the amyloid plaques characteristic of Alzheimer’s disease, has become central to diagnosis and to the growing field of disease-modifying Alzheimer’s therapy. A study of nearly 1,500 amyloid PET scans compared interpretations by local radiologists and nuclear medicine physicians with those of expert readers across three FDA-approved tracers. The good news: agreement was consistently strong, with similar performance for positive and negative scans. Importantly, the study also found that lower reader confidence was associated with reduced agreement, suggesting that confidence ratings could serve as a quality-control signal in routine practice. As amyloid PET demand surges worldwide, the findings provide reassurance that community-based interpretation can keep pace with expert standards.

Prostate cancer, the most active arena in nuclear medicine today, received an unusually detailed quantitative treatment. In a multicenter study, researchers evaluated measurements derived from 18F-piflufolastat PSMA PET/CT, matching PET findings with histopathology from 305 men to determine which imaging metrics best distinguish malignant prostate cancer from benign tissue. Several quantitative measures correlated with malignancy, but the SUVmax-to-blood-pool ratio showed the strongest ability to separate cancerous from benign lesions, both within the prostate and at metastatic sites. Establishing such thresholds is a critical step toward standardizing PSMA PET interpretation, reducing unnecessary biopsies, and enabling radiologists to report results with quantitative, reproducible criteria rather than subjective visual assessment alone.

Combination therapy, meanwhile, may soon be guided by a simple blood test and a PET scan. In an analysis of 37 patients with metastatic castration-resistant prostate cancer receiving 177Lu-PSMA-617 together with pembrolizumab, an immune checkpoint inhibitor, researchers examined whether baseline biomarkers could predict response. Patients with lower levels of circulating tumor DNA at the start of treatment and higher PSMA uptake on PET fared better, while changes in circulating tumor DNA and PSMA PET measurements at 12 weeks reflected both the depth and durability of response. The study points toward a practical biomarker strategy for selecting patients for combined radioligand immunotherapy, one of the most closely watched approaches in advanced prostate cancer.

Breast and kidney cancer imaging rounded out the new research portfolio. In triple-negative breast cancer, the most aggressive breast cancer subtype, a study compared 18F-ATD001, a PARP-targeted PET tracer, with standard 18F-FDG PET/CT in 37 women. The two methods detected similar numbers of lesions, and although the PARP tracer showed lower overall uptake, its signal correlated moderately with FDG in primary tumors, suggesting it may provide complementary biological information about DNA repair enzyme expression that FDG cannot capture. Separately, a prospective study of 68Ga-DPI-4452, a tracer targeting carbonic anhydrase IX, evaluated 30 adults with suspected kidney tumors. The agent identified clear cell renal cell carcinoma with high sensitivity and detected substantially more metastatic lesions than conventional imaging, with tracer uptake strongly correlating with CAIX expression in tumor tissue, a combination of diagnostic accuracy and biological validation that could reshape renal cancer imaging.

Taken together, the ahead-of-print collection paints a picture of a field in confident ascent. Tracers are becoming more biologically specific, imaging metrics are being quantified against gold-standard pathology, and therapy is increasingly delivered by molecules that home in on cancer cells while sparing healthy tissue. From macrophage mapping in head and neck cancer to DLL3 imaging in children with relapsed neuroblastoma, the studies collectively advance the central promise of nuclear medicine and theranostics: diagnosing and treating each patient according to the unique molecular fingerprint of their disease, with the goal of achieving the best possible outcomes.

Subject of Research: Advances in molecular imaging and radiopharmaceutical therapy reported in The Journal of Nuclear Medicine ahead-of-print research

Article Title: The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 11, 2026

Article References: The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 11, 2026. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: nuclear medicine, PET imaging, theranostics, radiopharmaceutical therapy, PSMA PET, neuroendocrine tumors, neuroblastoma, amyloid PET, prostate cancer, triple-negative breast cancer, kidney cancer, tumor-associated macrophages

The research, led by Chih-Ying Huang and colleagues at Taipei Veterans General Hospital and National Yang Ming Chiao Tung University in Taiwan, set out to determine whether fully automated AI segmentation could extract meaningful three-dimensional volumetric features from routine pre-treatment CT scans and whether those features correlated with outcomes after cryoablation for renal cell carcinoma. Rather than asking radiologists to eyeball categorical scores, the team deployed two deep learning tools to do the measuring: TotalSegmentator, a robust open-source system capable of segmenting more than 100 anatomic structures in CT images, and a model developed for the 2023 Kidney and Tumor Segmentation Challenge (KiTS23). Both are built on the nnU-Net framework, a self-configuring deep learning architecture that has become a workhorse of modern biomedical image segmentation.

The technical workflow is deceptively simple. For each patient, the pre-treatment nephrographic-phase contrast-enhanced CT scan was fed into the segmentation pipeline, which generated masks for the kidneys, renal tumors, and renal cysts. Masks for the renal sinuses, the central fat-filled cavity of the kidney that houses the collecting system and major blood vessels, were produced through a geometry-based approach described in the study’s supplementary material. Once the masks were generated, the software extracted a series of quantitative 3D features: tumor volume, an automated RENAL nephrometry score, the minimum distance between tumor and renal sinus, and a novel metric called tumor-renal sinus contact area, which quantifies the surface area over which the tumor directly abuts the renal sinus. On a GPU-accelerated workstation, the entire process took approximately five minutes per case, with an additional five minutes when manual correction was needed.

That manual correction proved to be the exception rather than the rule. Of the 116 patients in the study, only 16 required any adjustment to the automated masks, and most of those involved tumors lying adjacent to renal cysts or cases in which the algorithm failed to identify the tumor at all. No case required complete re-segmentation. This level of automation matters because conventional nephrometry scores suffer from well-documented interobserver variability. The R component of the RENAL score, for example, is measured on orthogonal planes and may not reflect the true maximal three-dimensional extent of a tumor, while the exophytic and location components have shown low perfect agreement among human readers. Continuous volumetric features extracted by software sidestep both problems, offering objective, reproducible numbers that capture anatomy in its full spatial complexity.

The study cohort consisted of 116 patients who underwent CT-guided percutaneous cryoablation for renal lesions at a single center between October 2009 and December 2024. The group comprised 85 men and 31 women with a mean age of 70.7 years, and the mean follow-up duration was 2.8 years. The mean tumor volume was 15.1 milliliters and the mean tumor diameter was 3.6 centimeters, consistent with the small, early-stage lesions for which ablation is typically recommended. Clear cell renal cell carcinoma was the most common histologic subtype, accounting for 64.7 percent of tumors. Notably, all cryoablation procedures throughout the fifteen-year inclusion window were performed by a single operator, which the authors suggest may have reduced variability related to procedural technique even as practice patterns evolved.

The clinical outcomes were assessed using standardized definitions from the International Working Group on Image-Guided Tumor Ablation and the SIO and DATECAN consensus guidelines. At the first post-ablation follow-up, 94 percent of patients achieved complete ablation, while 6 percent had residual unablated tumor requiring repeat cryoablation. Among those with complete initial ablation, 8 patients, or 6.9 percent of the cohort, later developed local tumor progression at the ablation margin. One patient with persistent tumor after re-ablation was ultimately found to have suspected venous invasion and a new lesion in the same kidney, requiring systemic therapy. To capture both early failure and later progression, the researchers defined a composite endpoint of local tumor control failure, combining residual unablated tumor and local tumor progression.

The statistical results pointed emphatically toward one feature. In univariable logistic regression, tumor volume, the RENAL nephrometry score, its R component, and tumor-renal sinus contact area were all significantly associated with local tumor control failure. But in a deliberately parsimonious multivariable model, limited by only 15 outcome events and bolstered by bootstrap resampling with 1,000 iterations to confirm coefficient stability, only tumor-renal sinus contact area remained independently predictive, with an odds ratio of 1.379 and a p-value of 0.002. The authors derived a composite risk score, calculated as 0.321 times the tumor-renal sinus contact area plus 0.023 times the tumor volume. In receiver operating characteristic analysis, this score achieved an area under the curve of 0.765 for predicting local tumor control failure, numerically higher than the 0.664 achieved by the RENAL nephrometry score, although the difference did not reach statistical significance on the DeLong test. With an optimal cutoff of 1.51, the score yielded a sensitivity of 67 percent and a specificity of 86 percent.

Two representative cases illustrate the score’s clinical texture. A 65-year-old man with biopsy-proven clear cell renal cell carcinoma had a 21.3-milliliter tumor with a tumor-renal sinus contact area of just 0.31 square centimeters, producing a risk score of 0.59, well below the cutoff. He underwent cryoablation and remained stable on follow-up imaging for more than four years. By contrast, a 91-year-old man with a similarly sized tumor of 25.2 milliliters but a contact area of 9.23 square centimeters scored 3.54, far above the threshold, and developed local tumor progression just nine months after treatment. In the Cox proportional hazards analysis, larger tumor-renal sinus contact area was also significantly associated with local tumor progression among patients who had achieved complete initial ablation, with a hazard ratio of 1.255 and a p-value of 0.026.

Why should contact with the renal sinus matter so much? The authors offer a biologically plausible but unproven explanation: the renal sinus contains major blood vessels whose continuous blood flow can dissipate cold energy from the ablation zone, a phenomenon known as the cold-sink effect. Tumors with extensive contact along the tumor-sinus interface may therefore be more susceptible to incomplete freezing, and indeed, viable tumor foci identified on follow-up imaging in this cohort were frequently located adjacent to the renal sinus. The researchers caution that this mechanism remains a hypothesis, since the study did not directly evaluate renal sinus vascular anatomy, tissue perfusion, intraprocedural temperature distribution, or ablation margin adequacy. Even so, the finding suggests that automated segmentation can capture an anatomically meaningful feature that is nearly impossible to quantify visually, information that existing categorical scoring systems simply do not encode.

The authors are careful to frame their conclusions as exploratory. The study was retrospective and single-center, the number of outcome events was small, the AI segmentation tools have not yet been formally validated across institutions and imaging protocols, and the composite risk score has not undergone external validation. Its discriminative performance was only moderate, and its incremental value over conventional predictors should be interpreted cautiously. Still, the implications are tantalizing. An objective, automated risk score generated in minutes from an existing CT scan could help clinicians identify anatomically challenging tumors, guide patient selection between ablation and surgery, and tailor surveillance intensity, with higher-risk patients potentially benefiting from closer imaging follow-up. Future work, the authors suggest, may extend the approach to segment renal vessels and ablation zones, register pre-treatment and intraprocedural images, and quantitatively assess ablation margins, bringing the field closer to a fully computational framework for predicting and ultimately preventing local treatment failure in kidney cancer.

Subject of Research: AI-based automated segmentation-derived 3D volumetric imaging features and outcomes after cryoablation for renal cell carcinoma

Article Title: Association between AI-based automated segmentation-derived 3D volumetric imaging features and outcomes after cryoablation for renal cell carcinoma

Article References: Huang, C.-Y., Hong, J.-A., Chang, N.-W., Li, C.-C., Liu, C.-A., & Shen, S.-H. (2026). Association between AI-based automated segmentation-derived 3D volumetric imaging features and outcomes after cryoablation for renal cell carcinoma. CVIR Oncology, 2(1), Article 24. https://doi.org/10.1007/s44343-026-00053-3

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00053-3

Keywords: renal cell carcinoma, cryoablation, artificial intelligence, automated segmentation, 3D volumetric imaging, tumor-renal sinus contact area, RENAL nephrometry score, tumor ablation, risk score, kidney cancer, radiology, predictive modeling

To appreciate why the finding resonates, it helps to revisit what KRAS actually does. The gene, located on chromosome 12, encodes a small signaling protein that operates like a molecular switch, cycling between an “off” state bound to GDP and an “on” state bound to GTP. Positioned just downstream of cell-surface receptors such as EGFR, KRAS relays growth signals into the RAF-MEK-ERK and PI3K-AKT cascades that instruct cells to proliferate. Mutations at codon 12 — together with codons 13 and 61 — cripple the protein’s ability to hydrolyze GTP back into GDP, wedging the switch in its active position and flooding the cell with growth commands. The G12C variant substitutes a glycine with a cysteine at position 12, and that single sulfur-bearing amino acid proved to be the opening drug hunters had awaited for a generation: covalent inhibitors such as sotorasib latch onto the reactive cysteine, trapping KRAS in its inactive, GDP-bound conformation and snapping the switch shut. Sotorasib became the first FDA-authorized agent directed against KRAS G12C, cementing the variant’s clinical importance where it is common — and raising the question of where else it might matter.

Despite that success in other cancers — most visibly non-small cell lung cancer, where the variant appears in a substantial fraction of adenocarcinomas — the frequency and genomic character of KRAS G12C in genitourinary malignancies had remained poorly defined. To close that gap, first author Kelly Crane and corresponding author K. R. Seetharam Bhat, affiliated with the Department of Urology at SUNY Upstate Medical University and Upstate Urology at MVHS, performed comprehensive genomic profiling of 13,654 metastatic tumor specimens: 1,453 renal clear cell carcinomas, 3,879 urothelial bladder carcinomas and 8,322 prostate acinar adenocarcinomas — the three major solid tumors of the genitourinary tract. Next-generation sequencing panels of this kind survey hundreds of cancer genes simultaneously, allowing even low-prevalence alterations to surface. The team also assessed tumor mutational burden, microsatellite instability and PD-L1 expression, the biomarkers that currently steer immunotherapy decisions in urothelial cancer. Published on August 19, 2026, the study asked a deceptively simple question: if KRAS G12C drugs already exist, how many patients with bladder, prostate or kidney cancer could ever qualify to receive them?

The answer, in raw numbers, is: very few, but not none. Across the full cohort, KRAS alterations appeared in 367 tumors, or 2.7 percent of specimens, reflecting the gene’s comparatively modest role in urologic malignancies against its dominance in pancreatic and lung cancers. Within that KRAS-altered population, only 25 tumors carried the G12C substitution — approximately 0.2 percent of all specimens and just under seven percent of all KRAS alterations detected. The researchers summarize the picture bluntly: “KRAS G12C mutations occur infrequently in major genitourinary malignancies.” The distribution, however, was anything but uniform. Not a single renal clear cell carcinoma harbored G12C, underscoring how biologically distinct kidney cancer remains. Urothelial bladder carcinoma emerged as the clear epicenter: KRAS was altered in roughly five percent of metastatic bladder tumors, and 24 of those 202 KRAS-altered cases — 12 percent — carried the druggable variant. Prostate acinar adenocarcinoma was nearly barren, with one G12C-positive tumor among 158 KRAS-altered specimens.

The bladder cancer data carried the study’s most intriguing biology. Compared with KRAS G12C-negative bladder tumors, the G12C-positive cases showed significantly fewer TERT co-alterations and significantly more KDM6A alterations — a pattern that sketches the outline of a molecularly distinct disease subset. TERT promoter alterations, which reactivate telomerase and grant cells unlimited replicative capacity, rank among the most common driver events in urothelial carcinoma, so their relative scarcity in G12C-positive tumors marks a meaningful departure from the standard genomic script. KDM6A, located on the X chromosome, encodes a histone demethylase that remodels chromatin and acts as a tumor suppressor; it is frequently disrupted in bladder cancer and has been linked in prior work to distinct transcriptional programs and immune phenotypes. The G12C-positive tumors also frequently carried alterations in TP53, the genome’s guardian gene, and in CDKN2A and CDKN2B, neighboring cell-cycle checkpoint genes on chromosome 9 whose loss releases the brakes on cell division. Together, the co-mutation landscape suggests that G12C-positive bladder tumors follow their own evolutionary route rather than borrowing the playbook of their KRAS-wild-type counterparts.

The lone G12C-positive prostate tumor offered a case study in miniature, carrying alterations in STK11 and APC alongside its KRAS mutation. STK11, also known as LKB1, is an energy-sensing kinase whose loss is a recognized modifier of KRAS-driven tumors and, in other cancer types, a documented influence on immunotherapy responsiveness; APC governs the Wnt signaling pathway. On the immunotherapy front, the biomarker data demanded caution. None of the KRAS G12C-positive tumors displayed microsatellite instability-high status, ruling out the mismatch-repair-deficient biology that predicts dramatic responses to checkpoint inhibitors. Median tumor mutational burden was somewhat higher in G12C-positive bladder tumors, and the single G12C-positive prostate case showed higher TMB than the other KRAS-mutated prostate specimens — suggestive of a heavier neoantigen load, but only suggestive. PD-L1 data were too sparse to interpret: just one of the 24 G12C-positive bladder tumors had undergone PD-L1 testing, rendering any statement about immune-checkpoint biomarkers in this subgroup statistically indefensible.

The clinical stakes rest on a therapeutic landscape that is expanding quickly. Sotorasib’s authorization proved that mutant KRAS can be pharmacologically cornered, and additional KRAS G12C inhibitors are moving through development and regulatory pipelines worldwide. The authors suggest that molecularly selected patients with genitourinary cancers could be considered for targeted strategies or basket-type clinical trials — studies that enroll patients according to a tumor’s genetic alteration rather than its organ of origin — as these drugs broaden their reach. The arithmetic favors vigilance over nihilism. A prevalence of 0.2 percent sounds negligible, but bladder cancer alone accounts for hundreds of thousands of new cases worldwide each year, and comprehensive genomic profiling has become routine enough at major centers to catch even single-digit-percentage events. “While these novel therapeutic approaches may not prove beneficial for the majority of patients with these malignancies, they may become integral in managing the subset of patients harboring the KRAS G12C alteration,” the authors write. For the 12 percent of KRAS-mutant bladder tumors carrying G12C, systematic genotyping could one day mark the difference between another line of chemotherapy and a precision-matched pill.

The investigators are candid about the study’s boundaries. Twenty-five G12C-positive tumors form a narrow foundation, comprising a single prostate cancer case and no renal clear cell carcinomas, which makes population-level generalization about those two tumor types impossible. As a retrospective analysis of already-profiled metastatic specimens, it captures a real-world population but inherits the blind spots of clinical testing patterns, and PD-L1 data were too thin to resolve the immune biomarker picture. Most importantly, the investigation measured genomic prevalence, not clinical response: no patient in the cohort received a KRAS G12C inhibitor as part of the study, so the findings map the molecular terrain without establishing whether sotorasib-class drugs actually shrink bladder or prostate tumors. That question now belongs to clinical trials. What the study does deliver is a map — an estimate of how many patients could be eligible, where they cluster, and what their tumors look like beyond the target mutation itself.

The broader message extends well beyond a single gene. Genitourinary oncology has accumulated druggable targets more slowly than lung or breast cancer, and studies like this one illustrate why comprehensive genomic profiling has become the field’s indispensable instrument: rare alterations become actionable only when someone systematically searches for them. As KRAS G12C inhibitors extend their footprint across tumor types, urothelial bladder carcinoma — with its small but consistent G12C-positive fraction and its distinctive KDM6A-rich, TERT-poor genomic signature — stands out as the genitourinary cancer most likely to host the next chapter of the KRAS-targeting story. More than thirty years after KRAS was written off as undruggable, the gene that once defined therapeutic frustration keeps redrawing the boundaries of what precision medicine can reach. For the small minority of patients whose tumors carry that single cysteine at position 12, the map has now been drawn; the next task is proving that the drugs work there, too.

News Publication Date: August 28, 2026

Web References: Oncotarget; Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine

References: Crane, K., et al. (2026). Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine. Oncotarget, 17. https://doi.org/10.18632/oncotarget.28912